Compare Abbott Laboratories (ABT) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Weibo Corp — how do they compare? Abbott Laboratories trades at $110.14 (market cap $187.95B), while Weibo Corp trades at $7.74 (market cap $1.93B). The key difference: Abbott Laboratories is far larger — about 97.4× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.75%). Which is the better fit depends on your goals.
| ABT | WB | |
|---|---|---|
Market Cap | $187.95B | $1.93B |
Sector | Health | Media |
52-Week High | $136.62 | $12.83 |
52-Week Low | $82.57 | $7.20 |
Enterprise Value | $214.96B | $1.20B |
Dividend Yield | 2.32% | 7.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Weibo (WB) trades at $7.98, up 0.5% with neutral technical signals. The stock shows compelling valuation metrics including a P/E of 5.5 and P/B of 0.5, trading below balance sheet value. Recent quarters show earnings misses but strong profitability with 21.15% net margin. Cash flow trends improved in 2025 with $408M net inflow, while revenue remains stable at $1.76B.
WB presents value opportunity with deep discount to fundamentals, though competitive pressures and recent earnings misses warrant caution. Analyst consensus leans bullish with 45% buy ratings, but structural challenges in user engagement and AI monetization create headwinds. The 8% dividend yield provides downside protection while investors await growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
